New genetic tool could unmask mystery brain infections in the tropics
NCT ID NCT07251049
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether next-generation sequencing can identify the infectious germs causing severe brain (encephalitis) and spinal cord (myelitis) inflammation in 100 patients in Guadeloupe. Many cases currently have no known cause. By analyzing spinal fluid, researchers hope to discover new or emerging pathogens specific to the tropics. This is an observational study, not a treatment, but could improve future diagnosis.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors identify unknown or emerging germs that cause severe brain infections, leading to better diagnosis and treatment in tropical regions.
- What could go wrong
- This is an observational study, not a treatment trial. It may not find new pathogens, and results may not apply to other populations or regions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2023
- Expected to finish
-
Nov 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with suspected acute infectious encephalitis and / or myelitis, according to the clinical and paraclinical criteria described in recommendations of the International Encephalitis Consortium in 2013 and the by the Transverse Myelitis Consortium Working Group in 2002
- Ages
-
28 days and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * We selected the following eligibility criteria for patients with acute encephalitis: * Patient of at least 28 days of life * With acute onset of symptoms for more than 24 hours * A major criterion among the following: * a disorder of consciousness or alertness * memory disorder * lethargy * modification of personal or behavioral disorder, irritability * confusion, disorientation in time or space \- At least two of the following minor criteria: * temperature above 38 ° C * new onset focal neurological deficit * epileptic crisis * biological abnormality of CSF (≥ 5 Leukocytes / mm3, protein ≥ 0.40 g / L) * partial or general epileptic seizure (s) not attributable to pre-existing epileptic disease and / or a recent focal neurological symptom * brain imaging suggestive of encephalitis, with EEG abnormalities suggestive of encephalitis * And absence of alternative diagnosis (intoxication, metabolic encephalopathy) * Persons affiliated or benefiting from a social security scheme; * Having given free, informed, written and signed consent by the patient or his legal representative (no later than the day of inclusion and prior to any review required by the research); * Eligibility criteria for Acute Transverse Myelitis Patients: * Patient of at least 28 days of life * Acute onset of symptoms for more than 24 hours * Medullary focal abnormality, responsible for motor, sensory or autonomic symptoms * contrast enhancement on bone marrow MRI and / or abnormal CSF (≥ 5GB / mm3, protein uptake ≥ 0.40 g / L) * Evolution between nadir and maximum symptoms, less than 4 weeks * Persons affiliated or benefiting from a social security scheme; * Having given free, informed, written and signed consent by the patient or his legal representative (no later than the day of inclusion and prior to any review required by the research); Exclusion Criteria: * Primary vasculitis of the central nervous system or a documented specific impairment in an autoimmune condition * Cerebral thrombophlebitis if not associated with encephalitis * Meningitis without clinical or paraclinical argument for cerebral parenchymal involvement * Pyogenic abscess * Cerebral or spinal abscess * Tumoral or hematological pathology of the central nervous system * Toxic or metabolic encephalopathy * Transverse myelitis with vascular or traumatic origin * Known chronic infection with HTLV virus
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute encephalitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre Hospitalier Universitaire de la Guadeloupe
RECRUITINGPointe-à-Pitre, Guadeloupe, 97159, Guadeloupe